Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.

BMC Gastroenterol · 2024 · PMC10759335 · PMID 38166671

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

There was a highly significant change in SBM frequency from baseline with elobixibat (10 mg and 15 mg) at Weeks 1 and 2 compared to placebo ( p < 0.0001) [ 44 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.